Achieved 200 Cases of CAR T-Cell Therapy
Samsung Medical Center is the first in Korea to establish a CAR T-cell Therapy Center and is operating a multidisciplinary-based treatment system. The professors from the Department of Hematology-Oncology and the Department of Pediatrics, along with specialized oncology nurses, are working together to provide comprehensive treatment for the patients. The center aims to improve treatment outcomes by creating a systematic care system for CAR T-cell therapy patients, alongside multidisciplinary treatment involving medical professionals from various departments, including laboratory medicine, neurology, infectious disease, and intensive care medicine.
Compared to the 52% treatment response rate reported in an international Phase 2 clinical study on CAR T-cells, Samsung Medical Center is leading with a 59% response rate. Last year, medical professionals, including Yao Ming, head of the Department of Pediatric Hematology and Oncology at National Taiwan University Hospital, visited to learn about the expertise and techniques involved in CAR T-cell therapy.
Center Director Kim, Won Seog stated, "We are the first to introduce CAR T-cell therapy in Korea, and we will continue to develop it into a leading center for CAR T-cell therapy in the future." He added, "By offering a wider range of treatment options, more hematologic cancer patients will receive better care." "We are committed to making this happen," he affirmed.